Mustang Bio terminates CD20 CAR-T license with Fred Hutch, pays $730K to settle $1.4M in payables

MUSTANG BIO, INC.

Terminated CD20 CAR-T license with Fred Hutch; agreed to pay $730,000 to settle ~$1.4M in outstanding payables.
Fred Hutch to pay Mustang at least 10% of consideration from any third-party CD20 licensing within three years.
All four proposals passed at Dec 22 annual meeting: directors elected, KPMG ratified, ESPP shares raised to 259,333, EIP to 2,514,666.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.